Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been given a consensus recommendation of “Buy” by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the stock […]